Rheumatoid Arthritis New Major Clinical Target for MSB
Filed with ASX · · 3 pages · English
In the deck
Later from Mesoblast
- Phase 3 Heart Failure Trial Size Substantially Reduced
- MSB Therapy Shows Benefit In First Cohort Of RA Patients
- Half Yearly Report and Accounts (including Appendix 4D)
- Increased Survival Using MSB Cells In Children With aGVHD
- GVHD Product Launched In Japan
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast